SCHEMBL13674530

SCHEMBL13674530

CC(=O)Nc1cccc(-c2ccc(CC3CCN(C4CCC(C)(O)CC4)C3=O)c(Cl)c2)c1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AVPR1A P37288 5/20 0.43
MCHR1 Q99705 5/20 0.40
OTUD7B Q6GQQ9 2/20 0.38
BMPR1B O00238 1/20 0.37
BMPR1A P36894 1/20 0.37
TGFBR1 P36897 1/20 0.37
ACVRL1 P37023 1/20 0.37
ACVR1 Q04771 1/20 0.37
ALPL P05186 1/20 0.36
ALPI P09923 1/20 0.36
ALPG P10696 1/20 0.36
KMT2A Q03164 1/20 0.36
HRH3 Q9Y5N1 1/20 0.36
FYN P06241 1/20 0.35
CMA1 P23946 1/20 0.35
CYP17A1 P05093 1/20 0.35
CYP11B1 P15538 1/20 0.35
CYP11B2 P19099 1/20 0.35
METAP2 P50579 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4515579 1.00 AVPR1A (0.43) AVPR1AMCHR1OTUD7BBMPR1BBMPR1A
SCHEMBL13675465 0.92 AVPR1A (0.42) AVPR1AMCHR1OTUD7BALPLALPI
SCHEMBL13674531 0.92 BMPR1B (0.38) AVPR1AMCHR1OTUD7BBMPR1BBMPR1A
SCHEMBL4528168 0.92 BMPR1B (0.38) AVPR1AMCHR1OTUD7BBMPR1BBMPR1A
SCHEMBL5548898 0.90 RORC (0.39) METAP2
SCHEMBL13674536 0.89 HRH3 (0.39) MCHR1BMPR1BBMPR1ATGFBR1ACVRL1
SCHEMBL5543774 0.89 HRH3 (0.39) MCHR1BMPR1BBMPR1ATGFBR1ACVRL1
SCHEMBL13674540 0.87 HSD11B1 (0.37) MCHR1BMPR1BBMPR1ATGFBR1ACVRL1
SCHEMBL4508940 0.87 HSD11B1 (0.37) MCHR1BMPR1BBMPR1ATGFBR1ACVRL1
SCHEMBL4508532 0.86 CHRM3 (0.40) OTUD7BBMPR1BBMPR1ATGFBR1ACVRL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes HSD11B1, HSD17B1, HSD11B2 AVPR1A 1954/4885MCHR1 2133/4885OTUD7B 2845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.